

Single Topic International Liver Cancer Association - ILCA

Workshop

WASHINGTON DC, USA / 26 SEPTEMBER 2026

Strategies in Resectable **Liver Malignancies**



In Partnership with:



Directed by 3 Internationally Renowned Hepatobiliary Surgeons

The ILCA-AHPBA Single Topic Workshop is led by three internationally recognized experts in hepatobiliary surgery, liver transplantation, and surgical oncology. Together, they have developed a cutting-edge scientific programme addressing the latest advances and challenges in liver cancer care.

ILCA-AHPBA STW Chairs representing ILCA



Dr. Gonzalo Sapisochin

Head of General and Digestive Surgery and Liver Transplantation, Vall d'Hebron University Hospital, Spain

An internationally recognized leader in transplant oncology and past ILCA Governing Board member, Dr. Sapisochin has advanced the role of liver transplantation and surgery in the treatment of liver cancer.



Dr. Adam Yopp

Chief of Surgical Oncology and Director of the Liver Tumor Program, UT Southwestern Medical Center, USA

Dr. Yopp is a leading surgical oncologist known for advancing multidisciplinary approaches to liver tumor management and improving patient outcomes.

ILCA-AHPBA STW Chair representing AHPBA



Dr. Shimul Shah

Chief of MGB Transplant Center and Division of Transplant Surgery, Mass General Brigham, USA

A globally recognized hepatobiliary and transplant surgeon, Dr. Shah is a leader in liver transplantation, surgical innovation, and multidisciplinary liver cancer care. He currently serves as President of AHPBA.

Under their leadership, the workshop will bring together international experts to explore the latest scientific advances, clinical innovation, and the future of multidisciplinary liver cancer care.

ILCA-AHPBA Single Topic Workshop Scientific Programme

26 September 2026

Time	Topic	Speakers
08:00 - 08:08	Welcome Remarks by STW chairs	
Session 1: How to define resectability in HCC?		
08:08 - 08:18	Eastern perspective	Catherine Teh, Philippines
08:18 - 08:28	Western perspective	Gonzalo Sapisochin, Spain
08:28 - 08:38	Implications for clinical trials	Adam Yopp, USA
Session 1: Present and futures perioperative strategies in HCC		
08:38 - 08:48	Implications for resection	Silvio Nadalin, Germany
08:48 - 08:58	Implications for transplant	Neil Mehta, USA
08:58 - 09:08	Implications for liver directed therapy	Ed Kim, USA
Session 1: Present and futures perioperative strategies in HCC		
09:08 - 09:18	Liver function and HCC - how to interpret and determine best treatment strategy	Sherrie Bhoori, Italy
09:18 - 09:28	How to determine the remnant and grow it if needed (TACE first, PV embo first, Bi-venular embolization)	Riad Salem, USA
09:28 - 09:38	Role of understanding genomic profile	
09:38 - 09:58	Discussion	All
09:58 - 10:30	COFFEE BREAK	
Debate 1: Resectable HCC - what should we do?		
10:30 - 10:40	Let's give neoadjuvant therapy first with I/O	Mark Yarchoan, USA
10:40 - 10:50	Lets do resection first	Albert Chan, Hong Kong
10:50 - 11:00	Lets do transplant as primary treatment	Karim Halazun, USA
11:00 - 11:10	How to monitor postop?	Anjana Pillai, USA
11:10 - 11:20	Neoadjuvant and adjuvant therapy in resectable HCC: Current evidence and clinical trials	
11:20 - 11:30	Role of ctDNA postop	
11:30 - 11:50	Discussion	All

ILCA-AHPBA Single Topic Workshop Scientific Programme

26 September 2026

Time	Topic	Speakers
11:50 - 12:50	LUNCH	Shimul Shah, USA
Session 2: Intrahepatic Cholangiocarcinoma		
12:50 - 13:00	Imaging-Based Diagnosis and Staging	So-Yeon Kim, South Korea
13:00 - 13:10	Role of targeted therapies	Haley Ellis, USA
13:10 - 13:20	Role of liquid biopsy and understanding genomic profile	Valerie Paradis, France
13:20 - 13:40	Discussion	All
Debate 2: Positive portal nodes on imaging - now what?		
13:40 - 13:50	Frame the discussion - why is it important?	Hop Tran Cao, USA
13:50 - 14:00	Resect first	Catherine Teh, Philippines
14:00 - 14:10	Neoadjuvant therapy first	Haley Ellis, USA
14:10 - 14:20	How important is nodal dissection for resection	Shimul Shah, USA
14:20 - 14:40	Discussion	All
Debate 3: Resectable solitary ICC		
14:40 - 14:50	Neoadjuvant therapy for all resectable lesions	Shishir Maithel, USA
14:50 - 15:00	Resect first since role of I/O is limited in most	Parissa Tabrizian, USA
15:00 - 15:10	Resect and put a pump in	Mike D'Angelica, USA
15:10 - 15:30	Discussion	
STW Closing Remarks CLOSING BY STW CHAIRS		

Join us in Washington!



Do not miss this year Single Topic Workshop **with great sessions and lively debates** from leading scientists and liver cancer specialists.

Registration is open.

Early bird rates available until **July 15, 2026**

Partner with ILCA to support scientific excellence and multidisciplinary collaboration in liver cancer, contact our sales team at:

ILCA Industry Relations
sales@ilca-online.org

International Liver Cancer Association (ILCA)
Avenue des arts 47
B-1000 Brussels, Belgium
T: +32 (0)2 320 2531

ilcalive.org

